Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964082 | 0.91 | TLR2 (0.49) | ALBSIRT2SIRT1SIRT3KMT2A | |
| SCHEMBL15964057 | 0.90 | ALB (0.46) | ALBKMT2ACA1CA2PTPN1 | |
| SCHEMBL31758278 | 0.86 | ALB (0.62) | ALBKMT2A | |
| SCHEMBL15962288 | 0.84 | ALB (0.55) | ALBSIRT2SIRT1SIRT3CA1 | |
| SCHEMBL17444823 | 0.84 | KLK7 (0.53) | SIRT2SIRT1SIRT3KMT2AHDAC1 | |
| SCHEMBL16790380 | 0.83 | CA1 (0.52) | SIRT2SIRT1SIRT3KMT2AHDAC1 | |
| SCHEMBL12214994 | 0.81 | MMP1 (0.49) | KMT2ACA1CA2 | |
| SCHEMBL15964099 | 0.81 | ALB (0.46) | ALBPTPN1 | |
| SCHEMBL14185324 | 0.80 | PTPN1 (0.49) | SIRT2SIRT1SIRT3KMT2AHDAC1 | |
| SCHEMBL14185326 | 0.80 | KLK7 (0.47) | SIRT2SIRT1SIRT3KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9295739-B2 | Folate conjugates of albumin-binding entities | Merck & Cie (CH) | 2016-03-29 | — | — | US | disclosed |
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-21 | — | — | US | disclosed |
| WO-2013024035-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | ALB, FOLR1, FOLR2 | ALB 1/4885SIRT2 2217/4885SIRT1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.